Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study

摘要

The role of serum uric add (SUA) as a prognostic marker for incident heart failure (HF) in hypertensive subjects is uncertain. We have prospectively examined the relationship between SUA and incident HF in 3440 men aged 60-79 years separately in those on and not on antihypertensive treatment who were followed up for a mean period of 15 years. Men on SUA lowering drugs and those with history of HF or myocardial infarction were excluded. There were 260 incident HF cases. The men were divided into three groups of SUA concentrations/levels (350, 350-410 and 410 mu mol/L). Raised SUA was associated with significantly increased risk of HF in men on antihypertensive treatment (N = 949) but not in those without (N = 2491) (p = 0.003 for interaction). In men on antihypertensive treatment those with hyperuricemia (410 mu mol/L) had the most adverse biological risk profile for HF including the highest rates of atrial fibrillation and renal dysfunction and the highest mean level of BMI, c-reactive protein and cardiac function (cardiac troponin T). Treated hypertensive men with SUA levels 410 mu mol/L showed an increase in risk of HF of more than twofold compared to those on treatment with levels 350 mu mol/L even after adjustment for lifestyle characteristics and biological risk factors [adjusted hazard ratio 2.26 (1.23,4.15)]. SUA improved prediction of HF beyond routine conventional risk factors (p = 0.02 for improvement in c statistics). SUA as a marker of increased xanthine oxidase activity may be a useful prognostic marker for HF risk in older men on antihypertensive treatment. (C) 2017 The Authors. Published by Elsevier Ireland Ltd.